Aytu BioPharma's GAAP loss for fiscal year 2021 was $58.289 million, up 4.3 times from $13.621 million in the previous year. Revenue increased 2.4 times to $65.632 million from $27.632 million a year earlier.
Aytu BioPharma's GAAP loss for fiscal year 2021 was $58.289 million, up 4.3 times from $13.621 million in the previous year. Revenue increased 2.4 times to $65.632 million from $27.632 million a year earlier. 
irdirect.net
English (US) 